Real‐world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide
Authors' conclusion
In this real-world study, patients with a pre-index HbA1c ≥7% who initiated treatment with oral semaglutide with a 7 or 14 mg maintenance dose had significantly lower HbA1c levels following treatment.
Study context
- Population
- Adults with T2D, pre-index HbA1c ≥7%, initiating oral semaglutide 1 Nov 2019–30 Jun 2020 with maintenance dose 7 or 14 mg; continuous enrolment ≥12 months pre-index and ≥6 months post-index
- Participants
- 520 adults
- Outcome
- Change in HbA1c between latest post-index and pre-index measurements
- Follow-up
- 6-month post-initiation period
Methodological detailsclaims-based, real-world, Patients received an average of 11.5 different medication classes pre-index
- Claims-based
- Real-world
- Patients received an average of 11.5 different medication classes pre-index
Main finding
As reported in the abstract
Mean HbA1c reduction, all patients · 6 months post-initiation
Mean HbA1c reduction (p < .001)
1.2%
Observational data: associations, not effects.
Further findings
Mean HbA1c reduction, persistent patients (≥90 days continuous treatment) · 6 months post-initiation
- Mean HbA1c reduction (p < .001)
- 1.4%
Original publication
Real‐world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide. Diabetes Obes Metab. Published 28 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →